How Do We Integrate Clinical Trial Data Without Losing Traceability?

How do we combine EDC, lab, ePRO, and imaging data for a clinical trial?

Combine the sources in layers. Keep each vendor delivery intact first. Load it into a raw zone with its delivery date, file name, vendor identity, protocol and study context. Do not overwrite it.

Then create a standardized review layer. Map each source field to a defined target field, retain the source record key, and attach the transformation version. EDC remains the place for its own collected data. The platform links it to lab, ePRO, imaging, and other records for review.

This distinction is the hinge. Original data is evidence. Harmonized data is a working view.

The FDA guidance on computerized systems used in clinical trials calls for clinical data used in safety and efficacy decisions to be attributable, original, accurate, contemporaneous, and legible. It also defines an audit trail as a secure, computer-generated, time-stamped record that reconstructs creation, modification, and deletion events.

Make the review screen answer four questions for every value: where did it originate, which delivery carried it, what mapping or transformation touched it, and who changed or approved its status? The FDA says data should be retrievable so information for each subject is attributable to that subject.

ePRO needs one extra question: who is the data originator? The FDA electronic source-data guidance states that when ePRO goes directly to an eCRF, the subject is the originator and the eCRF is the source. When a technology service provider database sits between them, that database is the source.

That source decision belongs in the design, not in a late review meeting. A review surface also needs clear interaction design; teams planning one can apply the same distinction between interface and underlying system described in Do I Need UI Design, UX Design, or Both for My Website?.

What data standards and mappings should be defined before integrating vendors?

Define a signed transfer specification and a source-to-target mapping before the first vendor file arrives. The specification names the contract. The mapping shows how the contract becomes usable trial data.

TransCelerate’s non-CRF data practices recommend documenting file naming, file format, content metadata, variable names and labels, allowable values and controlled terminology, delivery frequency, cumulative or incremental delivery, and blinding instructions. Add the protocol identifier, vendor record key, subject identifier rules, visit rules, collection date rules, missing-value rules, and correction process.

Write down the matching rule for each shared identity. A subject ID that looks alike is not proof of identity. State which system owns it, which fields form the match, and what happens when they disagree.

Use CDISC SDTM as the organizing standard where it fits the study’s downstream needs. CDISC describes SDTM as a standard for organizing and formatting data across collection, management, analysis, and reporting, and says each variable needs a clear definition. That is the reason a mapping sheet needs definitions, not only field names.

Version every mapping, terminology set, and transformation. Define-XML carries metadata about datasets, variables, controlled terms, and related structure for CDISC datasets. The CDISC Define-XML standard states that FDA and PMDA require it in each electronic submission to identify the metadata used. A transformation specification beside that metadata makes the path from vendor field to submission-facing field inspectable.

Test the transfer before production. Load a representative delivery, check record counts and required fields, test subject and visit matching, confirm blinded data stays blinded, and force at least one correction through the audit path. A clean file proves little. A recoverable failure proves the process.

How can a sponsor keep oversight when a CRO manages trial data?

A sponsor keeps oversight by retaining visibility and decision rights while the CRO runs assigned operations. The CRO can manage intake, checks, and vendor follow-up. The sponsor needs direct access to the status, evidence, and unresolved decisions.

Set a responsibility matrix for each source and each exception type. Name who receives the transfer, runs technical validation, reviews clinical meaning, reconciles records against EDC, requests a vendor correction, approves closure, and changes the mapping. TransCelerate recommends documenting roles for review, cleaning, and reconciliation, along with transfer and correction timelines.

Give sponsor users read access to the raw-delivery register, mapping versions, data-quality results, open discrepancies, closed-discrepancy rationale, and audit records. Restrict write access by role. The FDA says users who create, modify, or delete records should not be able to modify the audit trail.

Use a short review rhythm built around exceptions, not slide decks. Review new transfers, late or failed deliveries, unmatched subjects or visits, unresolved discrepancies, changed mappings, and risk indicators above their defined threshold. The record should show the state at that time, not a reconstructed story after the fact.

Risk-based monitoring works across sources when the platform preserves the route home. TransCelerate’s guidance on technology for risk-based monitoring says successful monitoring joins people, process, and technology, often through multiple integrated technologies. It describes lineage that reveals persistence points and every transformation, deviation, aggregation, or harmonization.

When a signal crosses a threshold, trace it back. A trend is not the evidence. The record is.